Effect of combined administration of clopidogrel and lysine acetylsalicylate versus clopidogrel and aspirin on platelet aggregation and activated GPIIb/IIIa expression in healthy volunteers

Author： Majluf-Cruz Abraham Chavez-Ochoa Adriana Ruiz de Majluf-Cruz Karim Coria-Ramirez Erika Pineda Del Aguila Ignacio Treviño-Perez Sandra Matías-Aguilar Lisneth López-Armenta Julio César Corona de la Peña Norma

Publisher： Informa Healthcare

ISSN： 1369-1635

Source： Platelets, Vol.17, Iss.2, 2006-03, pp. : 105-107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Platelet activation contributes to thrombotic events in cardiovascular disease. Acetylsalicylic acid (ASA) is used in combination with clopidogrel to reduce cardiovascular events. Lysine acetylsalicylate (L-ASA), also inhibits platelet activation with fewer gastrointestinal side effects than ASA. Dual therapy with L-ASA and clopidogrel may result in an antiplatelet effect with fewer side effects. We compared the antiplatelet effect of combined ASA/clopidogrel versus L-ASA/clopidogrel in healthy subjects. Fourteen volunteers (seven men and seven women, aged 25–45 years) received antiplatelet therapy during 14-day periods in the following sequence: 75?mg ASA; 160?mg L-ASA; 75?mg clopidogrel; 160?mg L-ASA plus 75?mg clopidogrel, and 75?mg ASA plus 75?mg clopidogrel. We evaluated platelet aggregation and glycoprotein IIb/IIIa activation. Our results show that administration of L-ASA/clopidogrel is as effective as ASA/clopidogrel combination.